Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Consistent reduction in the annualized rate of brain volume loss across phase 3 core and extension trials of fingolimod in relapsing multiple sclerosis
Multiple Sclerosis
(-)
180
Authors/Disclosures
Ernst-Wilhelm Radue, MD (Medical Image Analysis Center)
PRESENTER 		Dr. Radue has nothing to disclose.
No disclosure on file
Peter S. Chin, MD (Denali) No disclosure on file
Daniela Piani Meier Daniela Piani Meier has received personal compensation for serving as an employee of Novartis Pharma AG.
Howard I. Hurtig, MD (University of Pennsylvania) No disclosure on file
Nicolaos Sfikas (Novartis Pharma AG) No disclosure on file
Frederik Barkhof, MD, PhD (Image Analysis Center) Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Frederik Barkhof has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Combinostics. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IXICO. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI.